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ABSTRACT: Vitamin A derived retinoid compounds have multiple, powerful roles in the
cellular growth and development cycle and, as a result, have attracted signiﬁcant attention
from both academic and pharmaceutical research in developing and characterizing synthetic
retinoid analogues. Simplifying the hit development workﬂow for retinoid signaling will
improve options available for tackling related pathologies, including tumor growth and
neurodegeneration. Here, we present a novel assay that employs an intrinsically ﬂuorescent
synthetic retinoid, DC271, which allows direct measurement of the binding of nonlabeled
compounds to relevant proteins. The method allows for straightforward initial
measurement of binding using existing compound libraries and is followed by calculation
of binding constants using a dilution series of plausible hits. The ease of use, high
throughput format, and measurement of both qualitative and quantitative binding oﬀer a new direction for retinoid-related
pharmacological development.
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Retinoids are a class of molecules derived from vitamin A,which play a wide and active role within the growth and
development cycle of mammalian cells.1 This control over cell
diﬀerentiation, proliferation, and apoptosis is mediated by the
interaction of all-trans retinoic acid (ATRA, Figure 1) with the
retinoic acid receptor (RAR) proteins, which form DNA
binding heterodimers with the related retinoid X receptors
(RXR).1,2 The recruitment of these retinoid-bound hetero-
dimers to retinoic acid response elements (RARE), based
around a DR5 hexameric core motif, (A/G)G(G/T)TCA,
triggers expression of proteins and subsequent phenotype
change.1,3,4
Retinoids also form an important class of therapeutic agents
used in chemotherapy, as well as in alleviating severe skin
conditions.5 Additionally, there is growing evidence to suggest
that ATRA is capable of reducing levels of amyloid-β built up
in neurological tissues which may oﬀer a route to the treatment
of Alzheimer’s disease, and other conditions thought to be
related to amyloid-β.6 As a family, retinoids exhibit powerful
control over the workings of the human body and oﬀer great
promise for the modiﬁcation of these systems as drug
candidates.7,8
Cellular retinoic acid binding proteins, CRABP-I and
CRABP-II, are small, intracellular shuttling proteins associated
with retinoic acid traﬃcking in the cytosol.9 The two exhibit
signiﬁcant diﬀerences in expression levels and localization, with
CRABP-I being expressed in most adult cells and CRABP-II
being found mainly in the skin and early development
tissues.10
CRABP-II alone is capable of nuclear localization and is
demonstrably responsible for increasing the transcriptional
output of the retinoic acid signaling pathway. Accordingly, it is
understood that it is responsible for traﬃcking ATRA to the
nucleus, and to the DNA binding transcription factors, after its
arrival in the cytoplasm.11 Due to this deep involvement in the
retinoid signaling pathway, CRABP-II can be considered a
protein of signiﬁcant biological importance.
ATRA, speciﬁcally its conjugated polyene tail, is prone to
isomerization and degradation under 300−400 nm light. The
resulting mixture of ATRA, 9-cis, and 13-trans isomers is far
less eﬀective as a biological agent and, in turn, impacts the
reliability and consistency of quantitative work undertaken
using the compound.12 To circumvent this instability, synthetic
retinoids have been developed that mimic the shape of ATRA,
particularly the elongation and terminal carboxylate function,
but that do not share the compound’s predilection to
isomerization.13−15 One important example is EC23, a
synthetic analogue of ATRA that is entirely light stable and
carries out the same signaling role in stem cell diﬀerentiation
assays, but with improved potency.13,16
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DC271 is a further development of EC23, based on a
donor−acceptor diphenylacetylene structure, which exhibits
solvatochromic ﬂuorescence when excited at wavelengths
suitable for microscopy and as a ﬂuorescent probe (absorbing
at 340−410 nm).17,18 The compound’s emission is highly
dependent on the local environment; intense and blue-shifted
in nonpolar solvents, weak and red-shifted in polar solvents. In
an aqueous environment, in particular, the hydrophobic
structure of DC271 causes severe quenching of the emission,
ostensibly due to aggregation. This characteristic behavior can
be used to monitor incorporation of DC271 into the
hydrophobic binding pocket of a retinoid binding protein
(such as CRABP-II) where the insulated and hydrophobic
environment signiﬁcantly increases the quantum yield in an
analogous manner to a change to a nonpolar solvent.19,20
The unique ﬂuorescence characteristics of DC271 oﬀer a
novel and convenient method for direct measurement of
binding to retinoid-binding proteins, something previously
only achieved with complex and costly radio-labeling
techniques or multistep binding assays. Demonstrated herein
is the measurement of the binding of small molecules to
CRABP-II, in competition with DC271, as part of a high-
throughput capable assay. The action of CRABP-II as a carrier
protein makes this an ideal proof-of-principle experiment for
screening retinoid related molecules for potential pharmaceut-
ical eﬀect, a technique equally applicable to retinoic acid
receptor (RAR) proteins with vital downstream eﬀects on
phenotype.
To demonstrate the binding of synthetic retinoid DC271 to
CRABP-II, and conﬁrm the molecular basis of ligand binding,
crystallization trials in an informed range of conditions were
carried out resulting in a 1.5 Å resolution structure, which was
reﬁned to R/Rfree 0.14/0.17 (Figure 2, PDB 6HKR). The
ﬁtting of DC271 into the ligand binding site was carried out
using the unbiased density map calculated before crystallo-
graphic reﬁnements and the addition of water molecules. The
ﬁnal binding pose of DC271 was found to be highly congruent
with that of endogenous ligand ATRA, where the carboxylate
interacts with the same Arg112-Arg133-Tyr135 binding triad
(Figure 2, right). This structure demonstrates that DC271 is
capable of binding to CRABPII and that it occupies the
retinoid binding site of the protein. This, coupled with its
inherent solvatochromic ﬂuorescence, makes it an excellent
candidate for use in a displacement assay.
A ﬂuorescence displacement assay was carried out using a
series of endogenous retinoids as well as structurally related
fragments of DC271 (Figure 3A). This qualitative study was
carried out at multiple concentrations and gives an indication
of binding as a function of ligand displacement (relative
reduction in ﬂuorescent signal compared to the control) of
DC271 from the binding site. Black, nonbinding surface 96-
well plates were loaded with a 100 nM concentration of
Figure 1. Natural CRABP-II ligand all-trans retinoic acid (ATRA),
synthetic derivative EC23, and ﬂuorescent retinoid DC271.
Figure 2. (Left) Structural alignment of new CRABPII crystal structure 6HKR (DC271 bound, red) with reference structure 2FR3 (ATRA bound,
green). Close agreement of the carboxylic acid headgroup can be seen. (Right) Close-up view of the binding triad residues of 6HKR including
dashed hydrogen bonds, lengths marked in Å.
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CRABPII and DC271, as well as an aliquot of the tested ligand
or a relevant control. Each plate was read using a Biotek
Synergy H4 plate reader, in ﬂuorescence intensity mode,
exciting at 355 nm and reading emission at 460 nm.
These wavelengths were deemed the most suitable by
examination of the absorption/emission spectra and demon-
strate the useful near-visible ﬂuorescence of the compound.19
A Z′ value of >0.60 was routinely achieved, and the assay
shows several compounds with binding aﬃnity including
ATRA and 13-cis retinoic acid. 9-cis Retinoic acid, with its bent
shape a poor ﬁt for the CRABP-II binding site, demonstrated
comparatively ineﬀective displacement of DC271, with syn-
thesis fragments benzoic acid and quinoline also having no
eﬀect. These qualitative results conform to the known binding
aﬃnity of the respective compounds with CRABPII,22
demonstrating that the assay is truly indicative of active site
binding.
The reduction in ﬂuorescence observed when competing
ligands displace DC271 from the CRABP-II binding site can
also be applied to create a quantitative binding curve from a
serial dilution. The result of this experiment is shown in Figure
3 as a competitive binding screen using a varying concentration
of synthetic retinoid EC23. Subsequent ﬁtting of the curve
using DynaFit21 gives an estimated binding constant (Kd) of
160 nM, consistent with the reported activity of EC23 and
within the same nanomolar range previously reported for
ATRA binding to both CRABPII and CRABPII.16,23,24
This quantitative method is becoming increasingly relevant
and oﬀers more insight into a compound’s binding eﬃciency
than a single concentration library screen alone.25 Analogous
to a full competition titration, but using less material and
equipment time, the rapid evaluation of potential compounds
for binding eﬃciency will prove invaluable for hit-to-lead
progression, as well as in the development of isoform speciﬁc
binding compounds.
As a more powerful tool, it can be used most eﬀectively once
an initial screen has been carried out, or in complement to in
silico screening where a study can be focused on a smaller
number of higher likelihood candidates. Alternatively, an entire
library of compounds could be subjected to a qualitative
screen, generating a rich data set and reducing the opportunity
for false negatives/positives that can occur at single
concentrations. Given the wide range of compounds in the
ﬂuorescent DC series,18 adaptation of the assay for use with a
weaker binding ﬂuorescent retinoid would allow for inves-
tigation of compounds and fragments that exhibit lower
binding aﬃnities that may be diﬃcult to study.
The method demonstrated here comprises a simple 96-well
assay, which can be employed in medium to high throughput
screening, and oﬀers a quick indicator of binding aﬃnity to
CRABP-II, the cytosolic carrier protein that is crucial to
retinoid signaling activity at a cellular level. With further eﬀort
to optimize libraries and generate dilution series, a quantitative
experiment can be carried out to determine binding constants,
generating vital data for both hit-to-lead development
programs and in the development of compounds with isoform
speciﬁcity.
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Figure 3. (A) Qualitative displacement of DC271 from the binding
site of CRABP-II by select retinoids and retinoid related structural
components (n = 3, α = 0.05). (B) Quantitative measurement of
displacement of DC271 by synthetic retinoid EC23 (n = 3, α = 0.05).
Curve ﬁt using DynaFit21 in a competitive mode.
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